Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Wraps Up Finnzymes Acquisition

Premium

Thermo Fisher Scientific said last week that it has completed its acquisition of Finnish PCR products provider Finnzymes.

Thermo Fisher first announced the acquisition in early February. At the time, a Thermo official said that the acquisition was expected to bolster Thermo's PCR product portfolio, in particular by providing the company with its first PCR instrument platform.

Thermo also said that Finnzymes may provide it with a toehold in the burgeoning PCR-based molecular diagnostics market.

Financial terms of the acquisition have not been disclosed. Thermo previously said that the acquisition was not expected to impact its 2010 financial results.

Finnzymes, based in Espoo, has 90 employees and generated revenues of $20 million in 2009. It is unclear whether Thermo plans to retain Finnzymes' facilities in Espoo. Thermo did not respond to requests for comment.

Finnzymes manufactures the Phire and Phusion brand of DNA polymerases. The Phusion DNA polymerases are used in kits for amplifying DNA from whole blood and for bacterial profiling, while the Phire polymerases are used in kits to amplify DNA directly from a wide variety of animal and plant tissues.

Finnzymes claims that the polymerases outperform Taq-based polymerases in terms of speed and fidelity and are ideal for both routine and high-throughput PCR applications.

In addition, Finnzymes markets the Piko brand thermal cyclers. Available in 24- and 96-well formats, the Piko platform is about half the size of conventional thermal cyclers, yet the company claims they can complete a PCR protocol in as little as 10 minutes, which rivals or betters many other competing thermal cyclers.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.